New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...
Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.
Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Loose Women star Nadia Sawalha fought back tears as she paid tribute to her 'brave and selfless' friend who sadly passed away ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback